Aclaris Therapeutics
ACRS
137 hedge funds and large institutions have $480M invested in Aclaris Therapeutics in 2023 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 61 increasing their positions, 34 reducing their positions, and 16 closing their positions.
79% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 34
40% more call options, than puts
Call options by funds: $22.1M | Put options by funds: $15.8M
25% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 16
3% more funds holding
Funds holding: 133 → 137 (+4)
1.76% less ownership
Funds ownership: 100.6% → 98.84% (-1.8%)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
35% less capital invested
Capital invested by funds: $737M → $480M (-$257M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$31.6M |
| 2 |
Blackstone Inc
New York
|
+$10.7M |
| 3 |
Millennium Management
New York
|
+$9.75M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$6.36M |
| 5 |
ACM
Altium Capital Management
New York
|
+$3.44M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
B
Braidwell
Stamford,
Connecticut
|
-$30.1M |
| 2 |
Holocene Advisors
New York
|
-$15.4M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$9.18M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$7.97M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$5.62M |
ACRS Hedge Fund Activity: Q3 2023 in Review
137 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q3 2023, worth a combined $480M — down 35% from $737M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new ACRS positions and 16 closed out — a net gain of 4 holders — while 61 added to existing stakes and 34 trimmed.
The largest buyer was BVF Inc, adding an estimated $31.6M. The largest seller was Braidwell, exiting entirely with an estimated $30.1M sold.
- 137 institutional investors held Aclaris Therapeutics (ACRS) as of Q3 2023, up from 133 in Q2 2023.
- Funds reported $480M of Aclaris Therapeutics stock for Q3 2023, down 35% quarter-over-quarter.
- 20 funds opened new Aclaris Therapeutics positions in Q3 2023 and 16 closed out, a net change of +4 holders.
- The largest Aclaris Therapeutics buyer in Q3 2023 was BVF Inc, an estimated $31.6M added.
- The largest Aclaris Therapeutics seller in Q3 2023 was Braidwell, an estimated $30.1M sold.
Based on aggregated 13F filings for Q3 2023.